R&D News | pharmaphorum

News

Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward.

News

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

News

J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.

News

Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.

News

Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.

News

An observational study backed by Biogen has suggested that Apple smartphones and watches may be able to spot the signs of mild cognitive impairment.